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Recent Advances in IgA Nephropathy 
is a comprehensive compilation of 
basic science and clinical reviews 
of this common, primary kidney 
disease in the developed world. 
Lai has assembled 43 contributing 
authors from 13 countries who 
cover a vast number of historical 
and new developments over the 
past 10–15 years that have given 
us a better understanding of this 
enigmatic disorder. Although 
considered more often a primary 
renal disease, IgA nephropa-
thy has an important systemic 
component, as illustrated by the 
high rate of recurrence follow-
ing transplantation. Histologic 
evidence of  recurrent IgA 
nephropathy is observed in more 
than 35% of patients who receive 
renal allografts as treatment for 
end-stage kidney disease due to 
IgA nephropathy. When a kid-
ney obtained from a donor with 
asymptomatic IgA nephropathy is 
transplanted into a recipient with 
end-stage kidney disease due to 
a disease other than IgA nephro-
pathy, the deposits in the donor 
kidney rapidly disappear.
Shortcomings in a full com-
prehension of the disease are 
brought out in the book’s dis-
cussions on etiology, epidemiol-
ogy, genetics, pathogenesis, and 
clinical manifestations regarding 
prognosis. As an example, the 
list of genes responsible for, pre-
disposing to, or associated with 
renal progression continues to 
increase in number and complex-
ity, but a clear elucidation of their 
role in these disease attributes 
for familial IgA nephropathy, 
and the identification of variants 
for sporadic IgA nephro pathy, 
have not been achieved. More-
over, it is well known that IgA 
nephropathy is characterized by 
mesangial deposition of plasma 
cell–derived IgA1 that is under-
glycosylated and over represented 
in renal biopsy specimens. It is 
also known that the primary 
mucosal IgA immune response 
in patients with IgA nephropathy 
is disturbed by an IgA under-
response to mucosal challenge. 
However, there is no clear under-
standing of how this alteration 
in immune regulation is linked 
to the abnormal glycosylation 
of the IgA molecule, nor of how 
these fundamental alterations 
in the IgA molecular system 
orchestrate the profound cellu-
lar and immune responses that 
cause the nephropathy. Some, but 
not all, patients with IgA neph-
ropathy have elevated serum IgA 
levels or elevated levels of IgA 
in a complex with fibronectin. 
However, no antigen has been 
consistently detected in circulat-
ing immune complexes contain-
ing IgA or in biopsy specimens 
from the kidneys of patients with 
IgA nephropathy. A valuable 
addition to the book would have 
been a chapter describing a uni-
fying, conceptual approach to the 
pathogenesis of IgA nephropathy 
as it is understood today.
In the clinical chapters, it is 
noted that primary IgA nephrop-
athy is characterized by a highly 
variable course ranging from a 
totally benign condition to rap-
idly progressive renal failure. 
From 15% to 40% of patients will 
eventually have end-stage kidney 
disease. Chronic, slowly progres-
sive renal failure develops in most 
of these patients. Treatment has 
remained an enigma. The pros and 
cons of various treatments used 
over the past 40 years, includ-
ing corticosteroids, tonsillec-
tomy, renin–angiotensin system 
blockade, immunosuppressives, 
and other non-immunomodu-
lating agents, are presented in 
a balanced manner by authors, 
many of whom have led clinical 
trials testing the agents they dis-
cuss. It is especially important 
to point out that in all available 
studies there is a lack of clear, so-
called evidence-based treatment 
regimens that can be recom-
mended to slow renal progression 
for high-risk patients with IgA 
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nephropathy. The many studies 
that estimate event rates for clini-
cally significant end points have 
allowed clinical trials of treatment 
efficacy to be designed for such 
high-risk patients. More such tri-
als are needed in the future, as is 
pointed out in the discussions of 
existing therapies, and, hopefully, 
new treatment strategies can be 
designed that will be based on a 
better understanding of disease 
mechanisms and the ability to bet-
ter detect the disease in its early 
stages in those who are at risk.
Because of its comprehensive-
ness, Recent Advances is a welcome 
addition to the many treatises that 
have been published since Berger’s 
first two-page clinical description 
of IgA nephropathy in 1968. The 
book has a valuable place in the 
libraries of practicing nephrolo-
gists and investigators in the field. 
It is probably too detailed for 
undergraduate medical students 
and general internists.
